NCT04547309View on ClinicalTrials.gov

Research for the Molecular Imaging of the HER2 Targeting Tracer

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
HER2 Positive or Suspicious Positive Tumors
Interventions
RADIATION

68Ga/18F-HER2 Affibody PET/CT scan

HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.

Trial Locations (1)

100142

RECRUITING

Hua Zhu, Beijing

All Listed Sponsors
collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

North Sichuan Medical College

OTHER

lead

Peking University Cancer Hospital & Institute

OTHER